Published in AIDS Weekly, December 27th, 1999
In a clinical study, nine out of nine patients were treated with a single dose of this agent and tolerated the treatment with no side effects. Most notably, six out of six patients evaluated for a response of their disease showed reduction of their viral burden. These patients also showed a 3-to-5 fold enhancement of their immune function represented by their natural killer cells and B-cells.
The results of this study are reported by Hughes Institute...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.